JDBIO Co., Ltd. Participates in ‘AMWC Southeast Asia 2025’
Accelerating Southeast Asian Market Expansion with K-Medical Beauty Filler, Toxin, and Exosome Solutions
JDBIO Co., Ltd. participated in 'AMWC Southeast Asia 2025,' held at The Athenee Hotel in Bangkok, Thailand, from Thursday, November 20 to Friday, November 21, 2025, further strengthening its presence in the Southeast Asian medical aesthetics market.
AMWC Southeast Asia is the regional event of the globally influential Aesthetic & Anti-aging Medicine World Congress (AMWC), serving as a premier conference attended by leading international authorities in dermatology, plastic surgery, aesthetic medicine, and anti-aging. This year's event featured over 100 global companies and included various programs such as the latest medical aesthetic research findings, clinical trial data, innovative treatment protocols, live demonstrations, and hands-on workshops. Medical professionals and aesthetic practitioners were able to explore firsthand the latest filler trends, botulinum toxin injection protocols, and skin rejuvenation solutions.
Strong Interest in Filler, Toxin, and Exosome Portfolio
At the exhibition, JDBIO showcased its flagship products, including RICHESSE™ (Hyaluronic Acid Filler), One Tox® (Botulinum Toxin Type A), DEMEI™, JADE™, Exo'One (Exosome), OneFill™ (HA Dermal Filler), as well as its PDRN and PN booster lines, attracting considerable attention from global buyers and medical professionals.
In particular, JDBIO's portfolio of anti-aging and skin rejuvenation solutions generated strong interest among attendees from Southeast Asia and other international markets. Key product categories—including premium dermal fillers designed for facial contouring, botulinum toxin products aligned with the growing preference for natural-looking aesthetic outcomes, exosome-based skin boosters developed to support overall skin quality, and PDRN/PN-based solutions for skin revitalization—were among the highlights of discussions held throughout the event.
The positive response received during the exhibition reflected growing international interest in JDBIO's expanding medical aesthetics portfolio.
Throughout the exhibition, JDBIO held in-depth business meetings with clinics, medical professionals, and prospective distribution partners from Thailand, across Southeast Asia, and other international markets.
This event reaffirmed the rapidly growing demand for K-beauty medical products in the Southeast Asian region. It served as a vital opportunity to further refine filler and toxin product strategies tailored to the unique market characteristics and treatment trends of each country.
In addition, through the Coffee Break Lecture sessions and scientific programs held during the congress, JDBIO gained valuable insights into the latest trends in dermal filler treatments as well as emerging developments in skin rejuvenation and anti-aging research.
Through its participation in AMWC Southeast Asia 2025, JDBIO has established an important foundation for entering the Southeast Asian market. The company plans to continuously participate in major global exhibitions in the future to expand its influence as a leading K-medical beauty brand.
JDBIO Co., Ltd.